Skip to main content
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
DRUG DELIVERY
IMMUNOTHERAPIES
OLIGONUCLEOTIDE & NUCLEIC ACID
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
BRUSSELS, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
DRUG DELIVERY
IMMUNOTHERAPIES
OLIGONUCLEOTIDE & NUCLEIC ACID
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
BRUSSELS, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
DRUG DELIVERY
IMMUNOTHERAPIES
OLIGONUCLEOTIDE & NUCLEIC ACID
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
BRUSSELS, EU
PAST EVENTS
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Industry Experts
Loading
Wilbert Copeland
Scientific Associate Director,
Bristol Myers Squibb
Sessions
24-Feb-2025
09:05– 10:05
Machine learning as a method of modelling drug resistance mechanisms
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login
)
